HA
GSK icon

Herold Advisors’s GSK GSK Stock Holding History

Herold Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$484K Buy
9,213
+862
+10% +$45.6K 0.1% 179
2026
Q1 		$461K Buy
8,351
+240
+3% +$13K 0.1% 182
2025
Q4 		$398K Sell
8,111
-774
-9% -$36.1K 0.09% 184
2025
Q3 		$383K Sell
8,885
-1,548
-15% -$60.5K 0.09% 180
2025
Q2 		$401K Buy
10,433
+634
+6% +$24.2K 0.08% 206
2025
Q1 		$380K Sell
9,799
-360
-4% -$13.2K 0.08% 198
2024
Q4 		$344K Sell
10,159
-139
-1% -$5K 0.07% 208
2024
Q3 		$421K Sell
10,298
-395
-4% -$16.2K 0.09% 200
2024
Q2 		$412K Sell
10,693
-234
-2% -$9.84K 0.1% 196
2024
Q1 		$469K Buy
10,927
+246
+2% +$10.1K 0.11% 185
2023
Q4 		$396K Buy
10,681
+511
+5% +$18.3K 0.11% 182
2023
Q3 		$369K Sell
10,170
-9
-0.1% -$319 0.11% 183
2023
Q2 		$363K Sell
10,179
-372
-4% -$13.3K 0.11% 181
2023
Q1 		$375K Sell
10,551
-4,091
-28% -$143K 0.13% 161
2022
Q4 		$515K Sell
14,642
-11,916
-45% -$397K 0.22% 110
2022
Q3 		$781K Sell
26,558
-1,030
-4% -$39K 0.38% 88
2022
Q2 		$1.5M Buy
27,588
+1,226
+5% +$67.7K 0.67% 46
2022
Q1 		$1.44M Buy
26,362
+10,515
+66% +$571K 0.51% 64
2021
Q4 		$873K Buy
15,847
+2,083
+15% +$108K 0.34% 95
2021
Q3 		$657K Buy
+13,764
New +$691K 0.26% 104

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Herold Advisors's GSK Position: Q2 2026 in Review

Herold Advisors increased its GSK (GSK) stake by 10% in Q2 2026, buying an estimated $45.6K and bringing the position to 9,213 shares worth $484K. The position accounts for 0.1% of the portfolio, ranked #179.

Herold Advisors first reported a position in GSK in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.5M in Q2 2022. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Herold Advisors held 9,213 shares of GSK worth $484K as of Q2 2026.
  • Herold Advisors bought 862 GSK shares in Q2 2026, an estimated $45.6K.
  • GSK made up 0.1% of Herold Advisors's portfolio in Q2 2026, its #179 holding.
  • Herold Advisors first reported a position in GSK in Q3 2021 and has held it in 20 quarters since.
  • Herold Advisors's GSK position peaked at $1.5M in Q2 2022.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Herold Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.